Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain
- PMID: 21835156
- PMCID: PMC3181376
- DOI: 10.1016/j.ajpath.2011.07.001
Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by severe memory loss and cognitive impairment. Neuroinflammation, including the extensive production of pro-inflammatory molecules and the activation of microglia, has been implicated in the disease process. Tumor necrosis factor (TNF)-α, a prototypic pro-inflammatory cytokine, is elevated in AD, is neurotoxic, and colocalizes with amyloid plaques in AD animal models and human brains. We previously demonstrated that the expression of TNF-α is increased in AD mice at ages preceding the development of hallmark amyloid and tau pathological features and that long-term expression of this cytokine in these mice leads to marked neuronal death. Such observations suggest that TNF-α signaling promotes AD pathogenesis and that therapeutics suppressing this cytokine's activity may be beneficial. To dissect TNF-α receptor signaling requirements in AD, we generated triple-transgenic AD mice (3xTg-AD) lacking both TNF-α receptor 1 (TNF-RI) and 2 (TNF-RII), 3xTg-ADxTNF-RI/RII knock out, the cognate receptors of TNF-α. These mice exhibit enhanced amyloid and tau-related pathological features by the age of 15 months, in stark contrast to age-matched 3xTg-AD counterparts. Moreover, 3xTg-ADxTNF-RI/RII knock out-derived primary microglia reveal reduced amyloid-β phagocytic marker expression and phagocytosis activity, indicating that intact TNF-α receptor signaling is critical for microglial-mediated uptake of extracellular amyloid-β peptide pools. Overall, our results demonstrate that globally ablated TNF receptor signaling exacerbates pathogenesis and argues against long-term use of pan-anti-TNF-α inhibitors for the treatment of AD.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Figures







Similar articles
-
Chronic neuron- and age-selective down-regulation of TNF receptor expression in triple-transgenic Alzheimer disease mice leads to significant modulation of amyloid- and Tau-related pathologies.Am J Pathol. 2013 Jun;182(6):2285-97. doi: 10.1016/j.ajpath.2013.02.030. Epub 2013 Apr 6. Am J Pathol. 2013. PMID: 23567638 Free PMC article.
-
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice.Am J Pathol. 2008 Dec;173(6):1768-82. doi: 10.2353/ajpath.2008.080528. Epub 2008 Oct 30. Am J Pathol. 2008. PMID: 18974297 Free PMC article.
-
Genetic Deletion of Tumor Necrosis Factor-α Attenuates Amyloid-β Production and Decreases Amyloid Plaque Formation and Glial Response in the 5XFAD Model of Alzheimer's Disease.J Alzheimers Dis. 2017;60(1):165-181. doi: 10.3233/JAD-170065. J Alzheimers Dis. 2017. PMID: 28826177
-
Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?Curr Alzheimer Res. 2016;13(4):403-12. doi: 10.2174/1567205013666151116125714. Curr Alzheimer Res. 2016. PMID: 26567742 Review.
-
Targeting Microglia in Alzheimer's Disease: Pathogenesis and Potential Therapeutic Strategies.Biomolecules. 2024 Jul 11;14(7):833. doi: 10.3390/biom14070833. Biomolecules. 2024. PMID: 39062547 Free PMC article. Review.
Cited by
-
Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology.Neuropathol Appl Neurobiol. 2013 Feb;39(1):69-85. doi: 10.1111/nan.12002. Neuropathol Appl Neurobiol. 2013. PMID: 23171029 Free PMC article. Review.
-
Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer's disease.EMBO Mol Med. 2018 Apr;10(4):e8300. doi: 10.15252/emmm.201708300. EMBO Mol Med. 2018. PMID: 29472246 Free PMC article.
-
The effect of chronic periodontitis on serum levels of tumor necrosis factor-alpha in Alzheimer disease.Dent Res J (Isfahan). 2014 Sep;11(5):549-52. Dent Res J (Isfahan). 2014. PMID: 25426144 Free PMC article.
-
Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease.J Clin Cell Immunol. 2016 Aug;7(4):441. doi: 10.4172/2155-9899.1000441. Epub 2016 Aug 4. J Clin Cell Immunol. 2016. PMID: 27895978 Free PMC article.
-
Lipocalin 2: novel component of proinflammatory signaling in Alzheimer's disease.FASEB J. 2012 Jul;26(7):2811-23. doi: 10.1096/fj.11-202457. Epub 2012 Mar 21. FASEB J. 2012. PMID: 22441986 Free PMC article.
References
-
- McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:741–749. - PubMed
-
- Meda L., Cassatella M.A., Szendrei G.I., Otvos L., Jr, Baron P., Villalba M., Ferrari D., Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995;374:647–650. - PubMed
-
- Huberman M., Shalit F., Roth-Deri I., Gutman B., Brodie C., Kott E., Sredni B. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol. 1994;52:147–152. - PubMed
-
- Motta M., Imbesi R., Di Rosa M., Stivala F., Malaguarnera L. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett. 2007;114:46–51. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases